Go Pro
→ Why the Treasury still prices gold at 42 dollars an ounce (From Golden Portfolio) (Ad)tc pixel Free MDNA Stock Alerts

Medicenna Therapeutics (MDNA) Competitors

Medicenna Therapeutics logo
C$0.47 0.00 (0.00%)
As of 09/4/2026 02:09 PM Eastern
Compare

MDNA vs. BCT, HBP, SCYB, COM, and NVH

Should you buy Medicenna Therapeutics stock or one of its competitors? Medicenna Therapeutics's main competitors and comparable companies include BriaCell Therapeutics (BCT), Helix BioPharma (HBP), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), and Novoheart (NVH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Medicenna Therapeutics compare to BriaCell Therapeutics?

Medicenna Therapeutics (TSE:MDNA) and BriaCell Therapeutics (CVE:BCT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

0.4% of Medicenna Therapeutics shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A
BriaCell TherapeuticsN/AN/AN/A-C$0.38N/A

In the previous week, Medicenna Therapeutics had 1 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 1 mentions for Medicenna Therapeutics and 0 mentions for BriaCell Therapeutics. Medicenna Therapeutics' average media sentiment score of 0.00 equaled BriaCell Therapeutics'average media sentiment score.

Company Overall Sentiment
Medicenna Therapeutics Neutral
BriaCell Therapeutics Neutral

BriaCell Therapeutics has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. BriaCell Therapeutics' return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medicenna Therapeutics-533,640.00% -360.29% -32.80%
BriaCell Therapeutics N/A N/A N/A

Summary

Medicenna Therapeutics beats BriaCell Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Helix BioPharma?

Helix BioPharma (TSE:HBP) and Medicenna Therapeutics (TSE:MDNA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Helix BioPharma is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A

In the previous week, Helix BioPharma and Helix BioPharma both had 1 articles in the media. Helix BioPharma's average media sentiment score of 0.75 beat Medicenna Therapeutics' score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Helix BioPharma
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Medicenna Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Helix BioPharma has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. Helix BioPharma's return on equity of -21.54% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -21.54% -279.98%
Medicenna Therapeutics -533,640.00%-360.29%-32.80%

0.0% of Helix BioPharma shares are owned by institutional investors. Comparatively, 0.4% of Medicenna Therapeutics shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by company insiders. Comparatively, 22.6% of Medicenna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Helix BioPharma has a beta of 0.722962, meaning that its stock price is 28% less volatile than the broader market. Comparatively, Medicenna Therapeutics has a beta of 3.001413, meaning that its stock price is 200% more volatile than the broader market.

Summary

Medicenna Therapeutics beats Helix BioPharma on 6 of the 10 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Scythian Biosciences?

Medicenna Therapeutics (TSE:MDNA) and Scythian Biosciences (CVE:SCYB) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

In the previous week, Medicenna Therapeutics had 1 more articles in the media than Scythian Biosciences. MarketBeat recorded 1 mentions for Medicenna Therapeutics and 0 mentions for Scythian Biosciences. Medicenna Therapeutics' average media sentiment score of 0.00 equaled Scythian Biosciences'average media sentiment score.

Company Overall Sentiment
Medicenna Therapeutics Neutral
Scythian Biosciences Neutral

Scythian Biosciences has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. Scythian Biosciences' return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medicenna Therapeutics-533,640.00% -360.29% -32.80%
Scythian Biosciences N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A
Scythian BiosciencesN/AN/AN/AN/AN/A

0.4% of Medicenna Therapeutics shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Medicenna Therapeutics and Scythian Biosciences tied by winning 3 of the 6 factors compared between the two stocks.

How does Medicenna Therapeutics compare to 138267 (COM.TO)?

138267 (COM.TO) (TSE:COM) and Medicenna Therapeutics (TSE:MDNA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

In the previous week, Medicenna Therapeutics had 1 more articles in the media than 138267 (COM.TO). MarketBeat recorded 1 mentions for Medicenna Therapeutics and 0 mentions for 138267 (COM.TO). 138267 (COM.TO)'s average media sentiment score of 0.00 equaled Medicenna Therapeutics'average media sentiment score.

Company Overall Sentiment
138267 (COM.TO) Neutral
Medicenna Therapeutics Neutral

0.4% of Medicenna Therapeutics shares are held by institutional investors. 22.6% of Medicenna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
138267 (COM.TO)N/AN/AN/AN/AN/A
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A

138267 (COM.TO) has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. 138267 (COM.TO)'s return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
138267 (COM.TO)N/A N/A N/A
Medicenna Therapeutics -533,640.00%-360.29%-32.80%

Summary

138267 (COM.TO) and Medicenna Therapeutics tied by winning 3 of the 6 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Novoheart?

Novoheart (CVE:NVH) and Medicenna Therapeutics (TSE:MDNA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Novoheart has higher revenue and earnings than Medicenna Therapeutics. Novoheart is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoheartC$423.50K236.08-C$7.17M-C$0.04N/A
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A

0.4% of Medicenna Therapeutics shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Novoheart has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. Novoheart's return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
NovoheartN/A N/A N/A
Medicenna Therapeutics -533,640.00%-360.29%-32.80%

In the previous week, Medicenna Therapeutics had 1 more articles in the media than Novoheart. MarketBeat recorded 1 mentions for Medicenna Therapeutics and 0 mentions for Novoheart. Novoheart's average media sentiment score of 0.00 equaled Medicenna Therapeutics'average media sentiment score.

Company Overall Sentiment
Novoheart Neutral
Medicenna Therapeutics Neutral

Summary

Novoheart beats Medicenna Therapeutics on 6 of the 10 factors compared between the two stocks.

Get Medicenna Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MDNA vs. The Competition

Export
MetricMedicenna TherapeuticsBiotechnology IndustryHealthcare SectorTSE Exchange
Market CapC$43.38MC$4.01BC$7.25BC$12.64B
Dividend YieldN/A3.60%2.53%6.25%
P/E Ratio-2.1412.71273.5439.38
Price / SalesN/A1,370.28628.859.93
Price / Cash1.15108.6077.0882.29
Price / Book24.3416.1412.854.73
Net Income-C$25.98M-C$22.80MC$3.49BC$299.09M
7 Day Performance-1.05%0.31%1.04%-0.25%
1 Month Performance23.68%8.25%5.52%2.31%
1 Year Performance-55.24%49.17%24.39%27.86%

Medicenna Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MDNA
Medicenna Therapeutics
N/AC$0.47
flat		N/A-55.2%C$43.38MN/AN/A20
BCT
BriaCell Therapeutics
N/AC$10.60
-3.8%		N/A+0.0%C$168.68MN/AN/A5
HBP
Helix BioPharma
N/AC$1.90
flat		N/A+24.1%C$145.12MN/AN/A9
SCYB
Scythian Biosciences
N/AC$3.49
-5.9%		N/A+0.0%C$102.38MN/AN/AN/A
COM
138267 (COM.TO)
N/AN/AN/AN/AC$102.19MN/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:MDNA) was last updated on 9/6/2026 by MarketBeat.com Staff.
From Our Partners
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
This looks like plywood. It's not.
AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...
Eagle Publishing | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Why the Treasury still prices gold at 42 dollars an ounce
The U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...
Golden Portfolio | Sponsoredtc pixel
How to Think About a $500K Roth Conversion and the 35% Bracket
For 2026, the 35 percent federal tax bracket starts at 512,450 dollars in taxable income for joint filers and ...
SmartAsset | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel